Healthcare Policy

The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States...

Power is where power goes. Over the past few weeks, British politics has borne out Lyndon Johnson’s famous maxim. With the arrival of...

Last month saw the biggest overhaul in U.S. drug pricing regulation in decades. On Friday 12th August the Inflation Reduction Act was...

The long-awaited Women’s Health Strategy has been published. Its call for evidence in 2021 amassed over 100,000 responses – one of the...

Pharma and biotech, patients, payers, regulators and HTA agencies gathered at the World Evidence, Pricing and Access Congress in March...

Mental health has been on the margins of the European health debate for a long time. Yet, one in six people in the EU, or more than 84...

Nanomedicine is a complex and diverse term, encompassing the use of nanomaterials for the diagnosis, control, prevention, and...

The promise of innovative technologies is significant and is welcomed globally. The prospect of new therapies that could save and...

What should your pharma company talk about for the next twelve months?

It’s a question that many communications and public...

In 2017, former President of the European Commission Jean-Claude Juncker presented his White Paper on the Future of Europe:...

Many years in the making, the first CVDPREVENT audit report, published recently, gives a detailed snapshot of how those with...

With the recent performance of Cancer Waiting Times the worst on record, and predictions of thousands of ‘missing’ cancer patients...